BioCryst Pharmaceuticals (BCRX) reported Q4 adjusted loss Monday of $0.13 per diluted share, narrower from a loss of $0.28 a year earlier.
Four analysts polled by FactSet expected loss of $0.06.
Revenue for the quarter ended Dec. 31 was $131.5 million, up from $93.4 million a year earlier. Analysts surveyed by FactSet expected $130.1 million.
BioCryst Pharmaceuticals now expects full year 2025 total revenue of $560 million and $575 million, compared with the previous forecast of $540 million to $560 million. Analysts surveyed by FactSet expect $548.9 million.
Shares were down 3% in premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。